Premium
Antimonene Nanosheets‐Based Z‐Scheme Heterostructure with Enhanced Reactive Oxygen Species Generation and Photothermal Conversion Efficiency for Photonic Therapy of Cancer
Author(s) -
Kang Yong,
Li Zhengjun,
Yang Yanli,
Su Zhiguo,
Ji Xiaoyuan,
Zhang Songping
Publication year - 2021
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.202001835
Subject(s) - photothermal therapy , materials science , heterojunction , photosensitizer , photonics , nanomedicine , optoelectronics , nanoparticle , peg ratio , reactive oxygen species , photodynamic therapy , nanotechnology , photochemistry , chemistry , organic chemistry , biochemistry , finance , economics
A Z‐scheme heterojunction with high separation efficiency of photogenerated electrons and holes and enhanced reduction/oxidation potentials, which can enhance reactive oxygen species generation and photothermal conversion efficiency, exhibits tremendous potential in photonic theranostics. Herein, antimonene nanosheets (Sb NSs) are functionalized with photosensitizer 5,10,15,20‐Tetrakis(4‐hydroxy‐phenyl)‐21H,12H‐porphine (THPP) and a poly(ethylene glycol) (PEG) modifier. The Sb–THPP–PEG NSs thus fabricated are found to form a Z‐scheme heterojunction structure between Sb and THPP, based on their valence band and bandgap level analysis. The Z‐scheme heterojunction structure enables the Sb–THPP–PEG NSs multiple promising features for cancer therapy. Firstly, due to improved electron–hole pairs separation efficiency and redox potential, new reactive oxygen species •O 2 − is generated, besides the production of 1 O 2 by THPP. Secondly, the assembly of THPP enhances the NIR‐light‐to‐heat conversion of Sb NS, a photothermal conversion efficiency as high as 44.6% is obtained by this Sb–THPP–PEG NSs photonic nanomedicine. Moreover, the photothermal, fluorescent, and photoacoustic imaging properties of Sb–THPP–PEG NSs allow multimodal imaging‐guided tumor treatment.